To ask the Scottish Government what steps have been taken to accommodate the use of (a) anastrozole, (b) tamoxifen and (c) raloxifene as risk-reducing treatments for primary breast cancer (i) in existing and (ii) to develop new, clinical pathways. The National Cancer Medicines Advisory Group (NCMAG) will review the use of Anastrozole, Tamoxifen and Raloxif...